Walleye Capital LLC reduced its position in shares of Biotech Acquisition (NASDAQ:BIOT – Get Rating) by 13.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 81,797 shares of the company’s stock after selling 12,692 shares during the period. Walleye Capital LLC’s holdings in Biotech Acquisition were worth $807,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BIOT. DeepCurrents Investment Group LLC bought a new position in shares of Biotech Acquisition in the fourth quarter valued at approximately $174,000. BCK Capital Management LP acquired a new stake in Biotech Acquisition during the 1st quarter valued at $268,000. Spartan Fund Management Inc. bought a new position in Biotech Acquisition in the 1st quarter valued at $302,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in Biotech Acquisition in the first quarter worth $493,000. Finally, Glazer Capital LLC bought a new stake in shares of Biotech Acquisition during the fourth quarter worth $1,088,000. 86.02% of the stock is currently owned by institutional investors and hedge funds.
Biotech Acquisition Price Performance
Biotech Acquisition stock opened at $9.91 on Tuesday. Biotech Acquisition has a 12-month low of $8.30 and a 12-month high of $10.41. The stock has a 50-day simple moving average of $9.88 and a 200 day simple moving average of $9.84.
About Biotech Acquisition
Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
- Get a free copy of the StockNews.com research report on Biotech Acquisition (BIOT)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.